BC Innovations | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

Researchers are finding new ways to monitor the immune system in hematologic diseases that could have implications for optimizing immuno-oncology therapies, according to BioCentury’s analysis of emerging targets at ASH 2019. In abstracts released ahead...
BC Extra | May 17, 2019
Company News

May 17 Company Quick Takes: A trio of FDA approvals; plus Ligand/Cumulus, Revlimid

Takeda's Gattex gets pediatric approval  FDA approved Gattex teduglutide from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) to include treatment of patients age one and older with short bowel syndrome who are dependent on parenteral support,...
BC Extra | Apr 18, 2019
Company News

Talaris raises $100M series A, reports 70% immune tolerance for allogeneic cell therapy

With a new management team at the helm, Talaris raised $100 million in a series A round Thursday and reported that FCR001 led to a 70% immune tolerance rate in a Phase II trial to...
BC Week In Review | Oct 20, 2017
Clinical News

EC approves Amgen's Mimpara for pediatric indication

In August, Amgen Inc. (NASDAQ:AMGN) said the European Commission approved an expanded label for Mimpara cinacalcet (KRN1493, AMG 073) to treat secondary hyperparathyroidism not adequately controlled with standard therapy in patients ages ≥3 with end-stage...
BC Innovations | Jul 18, 2017
Distillery Techniques

Drug delivery; drug platforms

TECHNOLOGY: Nanoparticles; conjugates Antigen-capturing nanoparticles (AC-NPs) could enhance immune responses to radiotherapy plus checkpoint inhibitors to treat cancer. The AC-NPs consist of poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles that preferentially accumulate in tumors, modified to capture tumor...
BC Week In Review | Jul 7, 2017
Clinical News

EMA's CHMP recommends pediatric label expansion for Amgen's Mimpara

EMA’s CHMP recommended a label expansion for Mimpara cinacalcet (KRN1493, AMG 073) from Amgen Inc. (NASDAQ:AMGN) to include treatment of secondary hyperparathyroidism not adequately controlled with standard therapy in children ages ≥3 with end stage...
BC Innovations | Jan 26, 2017
Translation in Brief

Pickpocketed orphans

While G protein-coupled receptors (GPCRs) make good drug targets when the ligand is known, about 100 of the roughly 800-member family are orphan receptors, representing an untapped reservoir of potential drug targets. Now, researchers from...
BC Extra | Oct 27, 2015
Company News

PTAB institutes IPRs of Bass' Gattex petitions

The Patent Trial and Appeal Board of the U.S. Patent and Trademark Office instituted two inter partes review (IPR) petitions from Kyle Bass' Coalition for Affordable Drugs challenging patents covering Gattex teduglutide from Shire plc...
BC Innovations | Sep 17, 2015
Distillery Techniques

Techniques: RNA transcripts nanoparticles (RNAtr NPs) for tumor-targeted siRNA delivery

Drug delivery TECHNOLOGY: Nanoparticles RNA transcripts nanoparticles (RNAtr NPs) could be used to deliver siRNA to folate receptor-expressing tumors. The nanoparticles consist of compact, tandem copies of synthetic siRNA hybridized to DNA-cholesterol, which promotes self-assembly,...
BioCentury | Sep 14, 2015
Politics, Policy & Law

IPR battles

A bipartisan backlash against the pricing of specialty drugs has eroded the biopharma industry's political support, leading members of Congress to question whether efforts to exempt drug patents from the inter partes review system would...
Items per page:
1 - 10 of 667